Corsair Capital Management LP Has Decreased Pentair Plc (PNR) Stake By $1.99 Million; Sucampo Pharmaceuticals, Inc. (SCMP) Had 6 Bullish Analysts

October 13, 2017 - By Marguerite Chambers

Corsair Capital Management Lp decreased Pentair Plc (PNR) stake by 23.33% reported in 2017Q2 SEC filing. Corsair Capital Management Lp sold 30,171 shares as Pentair Plc (PNR)’s stock rose 15.45%. The Corsair Capital Management Lp holds 99,156 shares with $6.60M value, down from 129,327 last quarter. Pentair Plc now has $12.68 billion valuation. The stock increased 0.06% or $0.04 on October 12, reaching $69.89. About 8,675 shares traded. Pentair plc. Ordinary Share (NYSE:PNR) has risen 14.99% since October 13, 2016 and is uptrending. It has underperformed by 1.71% the S&P500.

Among 9 analysts covering Sucampo Pharma (NASDAQ:SCMP), 6 have Buy rating, 0 Sell and 3 Hold. Therefore 67% are positive. Sucampo Pharma had 31 analyst reports since August 6, 2015 according to SRatingsIntel. The stock of Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) has “Hold” rating given on Wednesday, August 16 by Jefferies. Mizuho maintained Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) on Friday, January 15 with “Neutral” rating. UBS maintained the stock with “Buy” rating in Thursday, October 12 report. The rating was maintained by Mizuho with “Neutral” on Monday, November 14. The rating was downgraded by Mizuho to “Neutral” on Thursday, August 4. The rating was reinitiated by Roth Capital with “Buy” on Thursday, October 29. The company was maintained on Wednesday, August 2 by Maxim Group. As per Wednesday, March 9, the company rating was maintained by Jefferies. The rating was downgraded by Mizuho on Tuesday, October 3 to “Neutral”. The rating was maintained by Jefferies on Thursday, August 4 with “Hold”. See Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) latest ratings:

12/10/2017 Broker: UBS Rating: Buy Old Target: $19 New Target: $15 Maintain
03/10/2017 Broker: Mizuho Old Rating: Buy New Rating: Neutral Downgrade
21/08/2017 Broker: Leerink Swann Rating: Outperform New Target: $15 Initiates Coverage On
16/08/2017 Broker: Jefferies Rating: Hold New Target: $11.0 Maintain
03/08/2017 Broker: Roth Capital Rating: Buy New Target: $30.0000 Maintain
02/08/2017 Broker: Maxim Group Rating: Buy New Target: $23.0000 Maintain
01/08/2017 Broker: Mizuho Rating: Buy New Target: $14.0000 Maintain
21/06/2017 Broker: Roth Capital Rating: Buy New Target: $29.5000 Maintain
09/06/2017 Broker: Jefferies Rating: Hold New Target: $11.0000 Maintain

Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company. The company has market cap of $484.15 million. The Firm is focused on the development and commercialization of pharmaceutical products. It currently has negative earnings. The Company’s primary focus areas are gastroenterology, ophthalmology and oncology-related disorders.

It closed at $10.4 lastly. It is down 5.30% since October 13, 2016 and is downtrending. It has underperformed by 22.00% the S&P500.

Investors sentiment decreased to 1.33 in Q2 2017. Its down 0.06, from 1.39 in 2017Q1. It is negative, as 23 investors sold Sucampo Pharmaceuticals, Inc. shares while 40 reduced holdings. 25 funds opened positions while 59 raised stakes. 24.71 million shares or 3.79% less from 25.68 million shares in 2017Q1 were reported. 42,818 were reported by California State Teachers Retirement Sys. Fdx Inc, California-based fund reported 11,107 shares. Royal Bank & Trust Of Canada holds 0% or 81,607 shares in its portfolio. The Pennsylvania-based Sei has invested 0% in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP). Goldman Sachs Grp reported 0% in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP). 103,949 are owned by Globeflex Capital Limited Partnership. Farmers And Merchants Invests stated it has 0% of its portfolio in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP). Lsv Asset Mngmt invested in 2.39 million shares or 0.04% of the stock. Nea Mgmt Company Ltd Liability Corporation accumulated 1.26M shares. Rhumbline Advisers holds 0% or 48,810 shares in its portfolio. Macquarie Gru Limited invested in 0% or 67,400 shares. The Ohio-based Bowling Management Llc has invested 0.21% in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP). Switzerland-based Credit Suisse Ag has invested 0% in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP). Pitcairn Communication holds 0.02% of its portfolio in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) for 14,085 shares. Glenmede Trust Na reported 225 shares.

Since May 15, 2017, it had 1 insider buy, and 3 selling transactions for $40.60 million activity. JONES DAVID A /WI had sold 10,000 shares worth $676,752. GARDEN EDWARD P also bought $56.31M worth of Pentair plc. Ordinary Share (NYSE:PNR) on Monday, May 15. 220,000 Pentair plc. Ordinary Share (NYSE:PNR) shares with value of $14.53M were sold by HOGAN RANDALL J. $503,325 worth of stock was sold by BORIN MARK C on Friday, May 19.

Among 23 analysts covering Pentair Inc. (NYSE:PNR), 8 have Buy rating, 3 Sell and 12 Hold. Therefore 35% are positive. Pentair Inc. had 64 analyst reports since July 22, 2015 according to SRatingsIntel. The company was downgraded on Wednesday, July 22 by Jefferies. RBC Capital Markets maintained Pentair plc. Ordinary Share (NYSE:PNR) on Wednesday, July 22 with “Outperform” rating. The company was initiated on Tuesday, April 5 by BMO Capital Markets. The firm has “Sell” rating by Cowen & Co given on Tuesday, May 30. The rating was maintained by RBC Capital Markets with “Outperform” on Wednesday, February 1. Cowen & Co maintained it with “Sell” rating and $5900 target in Thursday, July 20 report. The rating was downgraded by William Blair on Wednesday, July 22 to “Market Perform”. The firm earned “Hold” rating on Thursday, July 13 by Jefferies. On Wednesday, July 26 the stock rating was maintained by Morgan Stanley with “Overweight”. The company was maintained on Monday, August 22 by BMO Capital Markets.

Investors sentiment increased to 1.15 in 2017 Q2. Its up 0.06, from 1.09 in 2017Q1. It improved, as 27 investors sold PNR shares while 138 reduced holdings. 51 funds opened positions while 139 raised stakes. 153.84 million shares or 1.35% less from 155.95 million shares in 2017Q1 were reported. California-based Tcw Gru has invested 0.77% in Pentair plc. Ordinary Share (NYSE:PNR). Washington Tru Commercial Bank reported 1,135 shares. Schwab Charles Mngmt Incorporated has invested 0.04% in Pentair plc. Ordinary Share (NYSE:PNR). New Mexico Educational Retirement Board has invested 0.05% of its portfolio in Pentair plc. Ordinary Share (NYSE:PNR). Apg Asset Management Nv reported 180,328 shares stake. Somerset Trust holds 0.7% in Pentair plc. Ordinary Share (NYSE:PNR) or 19,219 shares. North Star Investment holds 5 shares or 0% of its portfolio. 15,672 were accumulated by Manning & Napier Advsrs Lc. Hudock Capital Grp Incorporated Limited Liability Corporation reported 8 shares. Virtus Advisers Inc stated it has 0.09% of its portfolio in Pentair plc. Ordinary Share (NYSE:PNR). D E Shaw And has 91,845 shares. Lpl Fincl holds 4,940 shares. Busey Tru holds 0.35% in Pentair plc. Ordinary Share (NYSE:PNR) or 37,809 shares. Reliance Trust Of Delaware has invested 0.11% in Pentair plc. Ordinary Share (NYSE:PNR). Cornerstone holds 0.02% in Pentair plc. Ordinary Share (NYSE:PNR) or 426 shares.

Analysts await Pentair plc. Ordinary Share (NYSE:PNR) to report earnings on October, 24. They expect $0.93 earnings per share, up 19.23% or $0.15 from last year’s $0.78 per share. PNR’s profit will be $168.73 million for 18.79 P/E if the $0.93 EPS becomes a reality. After $1.00 actual earnings per share reported by Pentair plc. Ordinary Share for the previous quarter, Wall Street now forecasts -7.00% negative EPS growth.

By

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

>
Twitter Auto Publish Powered By : XYZScripts.com